Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Bullboard Posts
Comment by Benedict16thon Oct 16, 2020 7:09am
65 Views
Post# 31726901

RE:RE:RE:RE:RE:GUDSMACKED - SLOWLY

RE:RE:RE:RE:RE:GUDSMACKED - SLOWLYInvestors buy share for capital appreciation and or dividends and not for 50%  capital loss and storytelling myths or long past success. Its all about the bottom line and Mr. JG is defenceless with not more narrative or excuses  to tell he is 100% responsible for the collapse of the share price. Is He not the CEO. Who is he going to blame this time around and will shareholders buy it?  GUD has been in control of GBT 51% since last November now for one full Year? Has anyone heard of any news “positive” or strategy about what is going on with GBT other than losing money and one drug rerelease? Ho yes I forgot  he has soemthing up the slleves six Years later! Well, if you have not it means GUD has not good news to tell one full year later.
Bullboard Posts